Lakewood-Amedex reports positive preclinical results for Bisphosphocin infection treatments
Compartilhar
Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) announced positive preclinical results for its Bisphosphocin compounds in animal models of urinary tract and pulmonary infections.
